Clinical Trial Update: Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study comparing pharmacokinetics and safety of Celltrion's CT-P52 against US-licensed ixekizumab (Taltz) in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• CT-P52
• TALTZ (IXEKIZUMAB)

Snippet

Sponsor: Celltrion | Conditions: Healthy Participants | Phase 1 | Status: ACTIVE_NOT_RECRUITING